Compare Citius Pharmaceuticals Inc (CTXR) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Orion Office REIT Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Orion Office REIT Inc trades at $2.68 (market cap $151.17M). The key difference: Orion Office REIT Inc is far larger — about 10.3× Citius Pharmaceuticals Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | ONL | |
|---|---|---|
Market Cap | $14.64M | $151.17M |
Sector | Health | Real Estate |
52-Week High | $1.82 | $3.04 |
52-Week Low | $0.53 | $1.93 |
Enterprise Value | $10.86M | $634.82M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
ONL trades at $2.72, down 1.09% today, with a bearish technical signal and negative earnings momentum. The company reported Q1 2026 EPS of -$0.24, missing expectations, while revenue declined to $147.65M in 2025. Despite a low P/B of 0.25, profitability remains weak with a -98.36% net margin. Recent news highlights strategic reviews and portfolio repositioning toward dedicated-use assets.
The outlook is cautious due to persistent losses and declining revenue, though strategic asset sales and debt management provide some stability. Risks include high leverage and office market challenges. Analyst sentiment is mixed with 50% buy ratings. Investment opportunity hinges on successful execution of strategic initiatives amid a difficult operating environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
